Building on these promising findings and the proven benefit of combining EGFR-TKIs with chemotherapy in advanced EGFR-mutated NSCLC, further clinical trials are underway to test this combination in the neoadjuvant context [57]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.